The August 2019 AHPA Report includes an analysis of FDA recall data, recent CA Prop 65 enforcement trends, the first warning letter addressing FSVP, insights from the Hemp-CBD Supplement Congress and updated guidance for hemp-CBD.
The July 2019 AHPA Report includes an open letter from AHPA President Michael McGuffin on his 20 years as AHPA President, recent CBD advocacy, AHPA's recommendations for supplement innovation, AHPA email alerts and much more.
China considers adding 5 functional ingredients, including reishi powder and spirulina, to its food raw materials directory, and changes to permitted health food function claims, in this issue of the IADSA Newsflash.
Congress passed a Farm Bill in 2018 that included historic provisions to legalize hemp, the low THC cultivars of the Cannabis sativa L. species. This landmark legislation changes how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S. To help the herbal products industry understand the new regulatory landscape, AHPA has expanded this Status Report and to answer industry questions about the new legal landscape.
2022 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.